ArticleKidney international reports2020
Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients.
Article in Kidney international reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Safety profile of belatacept in a real-life setting: disproportionality analysis of the WHO pharmacovigilance database.BMC pharmacology & toxicology · 2025Article
- Belatacept Conversion in Adolescent Kidney Transplant Recipients: A Solution for the Critical Challenge of Adherence?Kidney international reports · 2025Article
- Back to the Future With Co-Stimulation Blockade.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Time-Limited Therapy with Belatacept in Kidney Transplant Recipients.Journal of clinical medicine · 2022Article
- Converting Maintenance Kidney-Transplant Patients From Belatacept to Another Immunosuppressive Regimen: A Cautionary Tale.Kidney international reports · 2020Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDuring the coronavirus disease 2019 (Covid-19) pandemic, several physicians have questioned pursuing belatacept in kidney-transplant patients in order to reduce the risk of nosocomial transmission during the monthly infusion. The effect of the conversion from belatacept to another immunosuppressive regimen is underreported. The aim of the present retrospective study was to assess the effect on kidney function and the clinical outcome of the conversion from belatacept to another regimen.
methodsWe have identified 44 maintenance kidney transplantation patients from five French kidney transplantation centers who were converted from belatacept to another regimen either because of a complication (n = 28) or another reason (patients' request or belatacept shortage, n = 13). The follow-up after the conversion from belatacept was 27.5 ± 25.3 months.
resultsOverall, mean estimated glomerular filtration rate (eGFR) decreased from 44.2 ± 16 ml/min per 1.73 m
conclusionsThus, transplantation physicians should avoid stopping belatacept when not clinically required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.